![]() |
Welcome to Loot.co.za!
Sign in / Register |Wishlists & Gift Vouchers |Help | Advanced search
|
Your cart is empty |
||
|
Books > Medicine > Other branches of medicine > Pharmacology > General
This book is a compilation of past and recent knowledge in the field of emerging drug resistance. The book covers major aspects of drug resistance in bacteria, fungi, malaria, and cancer.Human survival on earth is constantly threatened by disease and syndrome. From the early days, the aim of research in medicine was to find therapeutic agents that can improve the quality of human life. Although humans are dependent on natural compounds from early days their dependence of drugs increased excessively in last century. The advances in chemistry and biology have helped researchers to identify the drugs that have improved treatment of many diseases. The primary factor for treatment of these diseases is dependent on the efficacy of drugs available. The development of resistance to these drugs is one of the major hindrances. Although there are number of books available on this topic, "drug resistance" biology across kingdoms has never been discussed in a coherent way.
Enzymes have interesting applications in our biological system and act as valuable biocatalysts. Their various functions allow enzymes to develop new drugs, detoxifications, and pharmaceutical chemistry. Research Advancements in Pharmaceutical, Nutritional, and Industrial Enzymology provides emerging research on biosynthesis, enzymatic treatments, and bioengineering of medicinal waste. While highlighting issues such as structural implications for drug development and food applications, this publication explores information on various applications of enzymes in pharmaceutical, nutritional, and industrial aspects. This book is a valuable resource for medical professionals, pharmacists, pharmaceutical companies, researchers, academics, and upper-level students seeking current information on developing scientific ideas for new drugs and other enzymatic advancements.
Founded in 1959, the series has moved from its initial focus on medicinal chemistry to a much wider scope. This volume encompasses all fields concerned with the development of therapeutic drugs, and the elucidation of their mechanisms of action. When combined with the other volumes, it serves as a time-saving source of information for researchers concerned with drug research, and all those who need to keep abreast of ongoing developments in medicines.
Medicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents. Antitumor chemotherapy is a very active field of research, and a huge amount of information on the topic is generated every year. Cytotoxic chemotherapy is gradually being supplemented by a new generation of drugs that recognize specific targets on the surface or inside cancer cells, and resistance to antitumor drugs continues to be investigated. While these therapies are in their infancy, they hold promise of more effective therapies with fewer side effects. Although many books are available that deal with clinical aspects of cancer chemotherapy, this book provides a sorely needed update from the point of view of medicinal chemistry and drug design.
This volume, is developed from a collaborative study sponsored by the World Health Organization over a period of five years, the result of the combined effort of over 30 experts working in 19 different countries. The book presents a comprehensive survey of the development, policy, and procedures of methadone maintenance in countries with experience in this treatment. In addition to presenting a general overview of methadone's role in treating opioid addiction, the volume also focuses on specific questions of current interest, particularly the critical issue of methadone maintenance in the prevention of AIDS. Public health specialists and policymakers will find this book an invaluable source of information about what can be expected from methadone maintenance programs and why such programs have achieved some success in the rehabilitation of opiate users, while so many other attempts in this area have failed. Following an introductory chapter, the contributors look at the impact of AIDS epidemiology on methadone policy. The role of methadone in addressing intravenous drug abuse and unsafe sex practices in drug dependent persons is explored in an attempt to assess the ability of methadone maintenance programs to stem the spread of AIDS. Subsequent chapters review the world literature on methadone in treating opioid dependency, explore national policies and practices regarding methadone maintenance, present an international survey of methadone's role, and analyze the present state of research on methadone. A bibliography and index complete the volume.
This book discusses cancers and the resurgence of public interest in plant-based and herbal drugs. It also describes ways of obtaining anti-cancer drugs from plants and improving their production using biotechnological techniques. It presents methods such as cell culture, shoot and root culture, hairy root culture, purification of plant raw materials, genetic engineering, optimization of culture conditions as well as metabolic engineering with examples of successes like taxol, shikonin, ingenol mebutate and podophylotoxin. In addition, it describes the applications and limitations of large-scale production of anti-cancer compounds using biotechnological means. Lastly, it discusses future economical and eco-friendly strategies for obtaining anti-cancer compounds using biotechnology.
Volksgeneeskuns in Suid-Afrika is ’n versameling van 8705 boererate en het die eerste keer in 1965 verskyn. Vandag, 60 jaar later, lyk die mediese en farmakologiese landskap totaal anders. Daarom is dit so interessant – en soms lagwekkend – om te sien hoe vinnig ons mediese en farmakologiese kennis intussen gevorder het. Die versameling bevat rate wat op bygeloof of tradisionele mondelinge oorlewering berus. Ander rate maak staat op veldkennis en die botaniese name van middels word verstrek. Daar word raat uitgedeel vir kwale van asma tot ylhoofdigheid. “Vermaaklike oomblikke is talryk vir die moderne leser – en die algemene gebruik van hondebloed, velle van pas geslagte katte, luislange en dies meer, laat ’n mens verbysterd – tot jy besef met hoeveel radeloosheid daar voor sekere siektes te staan gekom is.” Dr. Dione Prinsloo – geskiedkundige.
The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, and more. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results. Originally published by Bentham and now distributed by Elsevier, Anti-Angiogenesis Drug Discovery and Development, Volume 2 is an compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two decades. These reader-friendly chapters cover topics of great scientific importance, many of which are considered significant medical breakthroughs, making this book excellent reading both for the novice as well as for expert medicinal chemists and clinicians.
This volume focuses on antibiotics research, a field of topical significance for human health due to the worrying increase of nosocomial infections caused by multi-resistant bacteria. It covers several basic aspects, such as the evolution of antibiotic resistance and the influence of antibiotics on the gut microbiota, and addresses the search for novel pathogenicity blockers as well as historical aspects of antibiotics. Further topics include applied aspects, such as drug discovery based on biodiversity and genome mining, optimization of lead structures by medicinal chemistry, total synthesis and drug delivery technologies. Moreover, the development of vaccines as a valid alternative therapeutic approach is outlined, while the importance of epidemiological studies on important bacterial pathogens, the problems arising from the excessive use of antibiotics in animal breeding, and the development of innovative technologies for diagnosing the "bad bugs" are discussed in detail. Accordingly, the book will appeal to researchers and clinicians alike.
Originally published by Bentham and now distributed by Elsevier, Recent Advances in Medicinal Chemistry, Volume 1 covers leading-edge research and recent developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, drug targets, and natural product research and structure-activity relationship studies. The fourteen updated reviews include unique experimental data and references, and each article highlights an important topic in current medicinal chemistry research. Topics covered include: aureolic acid group of anti-cancer antibiotics and non-steroidal anti-inflammatory drugs; aromatase inhibitors in adjuvant endocrine treatment of early-stage breast cancer in postmenopausal women; Rho GTPases and statins in targeting and developing therapies for tumors; and more.
This is the first book on the market that explores the importance of curcumin for the treatment of neurological disorders. It has been estimated that 35.6 million people globally had dementia in 2010 and the prevalence of dementia has been predicted to double every 20 years. Thus, 115.4 million people may be living with dementia in 2050. Alzheimer's disease (AD) is the leading cause of dementia and is present in 60%-70% of people with dementia. Unless new discoveries are made in the prevention or treatment of AD, the number of cases in the US alone is estimated to increase threefold, to 13.2 million by the year 2050. Thus, it is important to focus on delaying and treating the onset of AD by curcumin may be an important step for controlling AD. Regular consumption of healthy diet containing curcumin enriched foods, moderate exercise, and regular sleep may produce beneficial effects not only on motor and cognitive functions, but also on memory deficits that occur to some extent during normal aging and to a large extent in AD. Delaying the onset and progression of AD and improving its symptoms by few years with regular consumption of curcumin may relieve some of the burden on health care systems. In service of this goal, this volume gives readers a comprehensive and cutting edge description of the importance of curcumin for the treatment of AD in cell culture and animal models in a manner that is useful not only to students and teachers but also to researchers, dietitians, nutritionists and physicians. It can be used as supplement text for a range of neuroscience and nutrition courses. Clinicians, neuroscientists, neurologists and pharmacologists will find this book useful for understanding molecular aspects of AD treatment by curcumin.
1. Prevention and Early Detection of Lung Cancer - Clinical Aspects.- 2. Smoking Prevention and Cessation.- 3. Clinical Pharmacology of Vitamin A and Retinoids.- 4. Early Lung Cancer Detection.- 5. Molecular Abnormalities in the Sequential Development of Lung Carcinoma.- 6. Application of In Situ PCR and In Situ Hybridization to the Characterization of Lung Cancers.- 7. Tumor Stroma Formation in Lung Cancer.- 8. Tumor Angiogenesis: Basis for New Prognostic Factors and New Anticancer Therapies.- 9. Cell Cycle Regulators and Mechanisms of Growth Control Evasion in Lung Cancer.- 10. Molecular Genetics of Lung Cancer.- 11. Neuropeptides, Signal Transduction and Small Cell Lung Cancer.- 12. In Vitro Analysis of Bombesin/Gastrin-Releasing Peptide Receptor (bb2) Ligand Binding and G-Protein Coupling.- 13. DNA Methylation Changes in Lung Cancer.- 14. K-ras Mutations as Molecular Markers of Lung Cancer.- 15. Sheep Lung Adenomatosis: A Model of Virally Induced Lung Cancer.- 16. Retinoic Acid Receptor ss An Exploration of its Role in Lung Cancer Suppression and its Potential in Cancer Prevention.- 17. Cytochrome P450 Polymorphisms: Risk Factors for Lung Cancer?.- 18. Glutathione S-Transferases and Lung Cancer Risk.- 19. The p53 Tumor Suppressor Gene in Lung Cancer: From Molecular to Serological Diagnosis.- 20. Endoscopic Localization of Preneoplastic Lung Lesions.- 21. Antigen Retrieval Improves hnRNP A2/B1 Immunohisto-chemical Localization in Premalignant Lesions of the Lung.- 22. Molecular Pathological Mechanisms in NSCLC and the Assessment of Individuals with a High Risk of Developing Lung Cancer.- 23. Chemoprevention of Lung Cancer.- 24. Regional Delivery of Retinoids: A New Approach to Early Lung Cancer Intervention.- 25. Natural Inhibitors of Carcinogenesis.- 26. Gene Delivery to Airways.- 27. Lung Cancer Prevention: The Point of View of a Public Health Epidemiologist.- 28. Biomarkers as Intermediate Endpoints in Chemoprevention Trials: Biological Basis of Lung Cancer Prevention.- 29. Biological Tools for Mass Screening.- 30. Optimization of the Use of Biological Samples for the Prospective Evaluation of Preneoplastic Lesions.
This book is designed to focus on the role of Calcitonin Gene-Related Peptide (CGRP) in health and disease. This peptide, originally discovered in the 1980s as a sensory neuropeptide with cardiovascular effects, is now known to play a distinct role in the pain processing of migraine. The various chapters address the origin, localization and function of CGRP and its receptor in the peripheral nervous system, in the cardiovascular system, and in other tissues and organs. Further attention is paid to the drug discovery pathway where recent findings show the beneficial effect of small molecule antagonists of the CGRP receptors for the relief of the migraine attack and of monoclonal antibodies against CGRP or the CGRP receptor for migraine prevention.
Silently orienting us to the world are traditions embedded in our language. These traditions shape how we understand the necessities and possibilities of life and truth. Dualism, a metaphysical theory, is such a tradition, and, in Keen's view, the separate discourses of science and morality create double meanings in our experience. Psychopharmacology is a critical intersection of these two worlds, where physical compounds are used to change mental life. Increasingly, the language of neurochemistry formulates that treatment. To control ennui with chemicals is to direct our attention away from what is wrong in our lives and to focus instead on what we can control easily, by taking a pill. Mental life has become marginal in biologically reductionistic discourse. While the demystification of human consciousness is surely a cornerstone of modernity, in excess it indulges a world design where nothing is sacred and everything becomes just another phenomenon to which we owe nothing. Our practice of manipulating consciousness as an object surrenders the complex reflections of moral ambiguity and struggle. Following the example of our doctors, Keen asserts, we the population neglect what is wrong in our lives. Like the rest of nature, our minds become exploitable. And properties of consciousness become commodities sold by prescription in drug stores. A provocative analysis of psychopharmacology this will be of interest to treatment professionals, from psychologists, psychiatrists, and nurses to social workers, as well as the interested public.
The pharmaceutical industry is currently operating under a business model that is not sustainable for the future. Given the high costs associated with drug development, there is a vital need to reform this process in order to provide safe and effective drugs while still securing a profit. Re-Engineering Clinical Trials evaluates the trends and challenges associated with the current drug development process and presents solutions that integrate the use of modern communication technologies, innovations and novel enrichment designs. This book focuses on the need to simplify drug development and offers you well-established methodologies and best practices based on real-world experiences from expert authors across industry and academia. Written for all those involved in clinical research, development and clinical trial design, this book provides a unique and valuable resource for streamlining the process, containing costs and increasing drug safety and effectiveness.
This detailed volume provides a single, valuable reference source for methods that definitively identify and accurately quantify apoptosis. The book begins with common methods utilized to detect and quantitate apoptosis, as well as apoptosis signaling pathways in toxicological and other related research. It continues with multi-parametric and phased apoptosis assays for detecting early and late apoptosis or distinguishing apoptosis from necrosis and autophagy. Subsequent chapters focus on recent advances in real time and high-throughput assays that detect and quantitate apoptosis and apoptosis signaling pathways. Final chapters focus on recent developments in preclinical anticancer therapeutics targeting apoptosis. Written for the Methods in Pharmacology and Toxicology series, chapters feature step-by-step descriptions of the methodologies, as well as expert tips and implementation advice. Vital and authoritative, Apoptosis Methods in Toxicology serves novice scientists as well as experts, utilizing a range of instruments from common laboratory equipment to high-end expensive and automated machinery capable of performing real time apoptotic measurements.
|
You may like...
Advanced Nanoformulations - Theranostic…
Md Saquib Hasnain, Amit Kumar Nayak, …
Paperback
R3,974
Discovery Miles 39 740
How Synthetic Drugs Work - Insights into…
Imran Kazmi, Sanmoy Karmakar, …
Paperback
R3,925
Discovery Miles 39 250
Drug Delivery Systems for Metabolic…
Harish Dureja, Narasimha Murthy, …
Paperback
R3,925
Discovery Miles 39 250
Prof. of Drug Substances, Excipients and…
Abdulrahman Al-Majed
Hardcover
R5,239
Discovery Miles 52 390
Herbal Bioactive-Based Drug Delivery…
Inderbir Singh Bakshi, Rajni Bala, …
Paperback
R3,967
Discovery Miles 39 670
Clinical Pharmacology During Pregnancy
Donald Mattison, Lee-Ann Halbert
Paperback
R2,515
Discovery Miles 25 150
Design of Nanostructures for Versatile…
Alexandru Mihai Grumezescu
Paperback
|